# US 2004/0023844 A1 · Method and device for controlling drug pharmacokinetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023844 A1
- Document ID: US20040023844A1
- Status: Published application
- Kind: A1
- Application number: 10/429,973
- Filed: 2003-05-06
- Published: 2004-02-05
- Earliest claimed: 2002-05-06
- Assignees: Becton, Dickinson and Company
- Inventors: Ronald J. Pettis; Noel Harvey; Barry Ginsberg
- Web page: https://patentgrep.com/patent/US20040023844A1

## CPC

- A61M 37/0015: {by using microneedles}
- A61M 5/3291: {Shafts with additional lateral openings}
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/0061: {Methods for using microneedles}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.

## Claims

### Claim 1

A method for delivering a therapeutic substance to a subject comprising delivering the substance within or beneath the skin at least into the intradermal space to access at least two compartments, which compartments afford the substance different pharmacokinetics, which enhance the effectiveness of the substance in terms of a resultant composite pharmacokinetics compared to delivery to a single compartment.

### Claim 2 (depends on 1)

The method of claim 1 wherein the substance is delivered to multiple sites that each include at least two compartments.

### Claim 3 (depends on 1)

The method of claim 1 wherein the delivery of the substance is by a needle or cannula.

### Claim 4 (depends on 3)

The method of claim 3 wherein a single needle or cannula is inserted into the intradermal space.

### Claim 5 (depends on 3)

The method of claim 3 wherein multiple needles or needle arrays are inserted into the intradermal space.

### Claim 6 (depends on 5)

The method of claim 5 wherein the multiple needles have different lengths.

### Claim 7 (depends on 3)

The method of claim 3 wherein the needle or cannula is about 300 μm to about 5 mm long.

### Claim 8 (depends on 7)

The method of claim 7 wherein the needle or cannula is about 500 μm to about 1 mm long.

### Claim 9 (depends on 3)

The method of claim 3 wherein the needle or cannula has an outlet placed at a depth of about 250 μm to about 2 mm when it is inserted into the intradermal space.

### Claim 10 (depends on 9)

The method of claim 9 wherein the outlet is at a depth of about 750 μm to about 1.5 mm when the needle or cannula is inserted.

### Claim 11 (depends on 10)

The method of claim 10 wherein the outlet has an exposed height of about 0 to about 1 mm.

### Claim 12 (depends on 11)

The method of claim 11 wherein the outlet has an exposed height of about 0 to about 300 μm.

### Claim 13 (depends on 1)

The method of claim 1 wherein the delivery of the substance is by a needle selected from the group consisting of microneedles, catheter needles, and injection needles.

### Claim 14 (depends on 1)

The method of claim 1 further comprising controlling the delivery rate or volume delivered of the substance to the intradermal space.

### Claim 15 (depends on 1)

The method of claim 1 wherein said delivery is controlled pursuant to an algorithm having logic components which include physiologic models, rules based models or moving average methods, therapy pharmacokinetic models, monitoring signal processing algorithms, predictive control models, or combinations thereof.

### Claim 16 (depends on 1)

The method of claim 1 wherein the multiple compartments are intradermal and subcutaneous tissue compartments.

### Claim 17 (depends on 1)

The method of claim 1 wherein access of the two or more compartments is by at least one needle that targets the ID compartment and at least another one needle that targets SC compartment.

### Claim 18 (depends on 1)

The method of claim 1 wherein access of the two or more compartments is by at least one needle which essentially simultaneously targets the ID compartment and SC compartment.

### Claim 19 (depends on 18)

The method of claim 18 wherein the needle or needles targets the SC compartment by overloading the ID compartment.

### Claim 20 (depends on 1)

The method of claim 1 wherein access of the two or more compartments is by at least one needle which sequentially targets the ID compartment and SC compartment.

### Claim 21 (depends on 1)

The method of claim 1 wherein delivery to multiple compartments is by at least one needle that targets the interface of the ID and SC compartments.

### Claim 22 (depends on 1)

The method of claim 1 wherein a portion of said therapeutic substance is absorbed more rapidly into an intradermal tissue space, and the remaining portion is absorbed less rapidly into a subcutaneous tissue space.

### Claim 23 (depends on 1)

The method of claim 1 wherein the enhanced effectiveness is a decrease in Tmax.

### Claim 24 (depends on 1)

The method of claim 1 wherein the enhanced effectiveness is an increase in Cmax.

### Claim 25 (depends on 1)

The method of claim 1 wherein the enhanced effectiveness is a decrease in Tlag.

### Claim 26 (depends on 1)

The method of claim 1 wherein the enhanced effectiveness is enhanced absorption rate.

### Claim 27 (depends on 1)

The method of claim 1 wherein the enhanced effectiveness is improved bioavailability.
